Current Trials
Current Trials
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy, Safety, and Tolerability of Vk2809 Administered for 52 Weeks Followed by a 4-Week Off-Drug Phase in Subjects with Biopsy Proven Non-Alcoholic Steatohepatitis With Fibrosiss
Evaluation of the diagnostic performance of the M30 Apoptosense®, M65 and M65 EpiDeath ELISA Assay Results to Stratify Non-Alcoholic Steatohepatitis (NASH) from simple steatosis in a Cohort of Patients Suspected of Non-alcoholic Fatty Liver Disease (NAFLD)
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Efficacy, Safety and Tolerability of HM15211 Treatment for 12 Months in Subjects With Biopsy Confirmed NASH
A Phase 3, Multinational, Double-Blind, Randomized, Placebo-Controlled Study of MGL-3196 (Resmetirom) in Patients With Non-Alcoholic Steatohepatitis (NASH) and Fibrosis to Resolve NASH and Reduce Progression to Cirrhosis and/or Hepatic Decompensation
Prospective Clinical Trial to Detect Liver Cancer Through Quantification of cfDNA Methylation in Blood Samples: A LAM Insight Trial Study
Closed Trials
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis
Procurement of Blood Samples from Subjects with Diagnosed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) for Use in the Development of a Liver Fibrosis Test
Multicenter, Prospective Evaluation of the Beckman Coulter DxN HCV Viral Load Assay as an aid in the Management of HCV-Infected Individuals Undergoing Antiviral Therapy
Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and Pharmacokinetics of MN-001 (tipelukast) on HDL (High Density Lipoprotein) Function and Serum Triglyceride Levels in Non-Alcoholic Steatohepatitis (NASH) Subjects with Hypertriglyceridemia.
Clinical Evaluation of the Xpert® HCV VL Assay
Multicenter, Prospective Evaluation of the Beckman Coulter DxN HBV Viral Load Assay as an Aid in the Management of HBV-Infected Individuals Undergoing Antiviral Therapy
A Multicenter, Double-Blind, Sponsor-Open Trial of IDN-6556 in Subjects Who had Hepatitis C Virus (HCV) Reinfection and Liver Fibrosis following Orthotopic Liver Transplantation for Chronic HCV Infection and Who Subsequently Achieved a Sustained Virologic Response Following anti-HCV Therapy
Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF
Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis (CLARITY)
Collection of Blood Specimens from Subjects Infected with Chronic Hepatitis C (Genotypes 2 and 3) and Treated with Sofosbuvir plus Ribavirin
A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072 (Champion2)
CTS-1027 in Interferon-Naive Hepatitis C Patients
Standard of Care (SOC) With or Without CTS-1027 in Hepatitis C (HCV) Null-Responders
Study of CTS-1027 in Hepatitis C Patients
Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)
AST-120 Used to Treat Mild Hepatic Encephalopathy (ASTUTE)
Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy (AST015)
A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection
Retrospective Review of Baseline, On-Treatment, and Outcome Data for Patients in the United States Treated With Telaprevir After Marketing Approval
Safety & Efficacy of the Extracorporeal Liver Assist Device (ELAD) System in Patient With Hepatic Insufficiency
Safety and Efficacy of the Extracorporeal Liver Assist Device (ELAD®) In Patients With Fulminant Hepatic Failure (FHF)
Efficacy and Safety of the Extracorporeal Liver Assist Device (ELAD) in Acute on Chronic Hepatitis (SILVER)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 2a Clinical Trial to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Orally Administered TERN-101 Tablets in Adult Patients with Presumed Non-Cirrhotic Non-Alcoholic Steatohepatitis (NASH)
A Randomized Phase II Study of First Cycle Optimization for Regorafenib Treatment Compared to Standard Dose of Regorafenib in Patients with HCC Who Failed Any 1st Line Systemic Treatment and for Whom the Physician is Intending to Treat with Regorafenib, ReDOS HCC-21305